Stroke Trials Registry

Dutch TIA
Dutch TIA Study

Study Size Actual:

3131

Status:
Trial results published 1991,1993.

Purpose:
To compare effects of atenolol vs placebo, and two doses of aspirin for stroke prevention.

Interventions:

Aspirin (stroke prevention)
Antiplatelet agent; inhibits thromboxane A2

Atenolol
Beta-adrenergic receptor antagonist (beta-blocker); anti-hypertensive

Year Started: 1987

Year Published: 1991

Design:
Double-blind, randomized, controlled, multicenter clinical trial.

Inclusion Criteria
Patients who had a transient ischemic attack or minor stroke.

Patient Involvement:
Two different therapeutic comparisons were made by double randomization: 30 mg vs. 300 mg acetylsalicylic acid, and 50 mg atenolol vs. placebo.

Primary Outcome:
Death from all vascular causes, nonfatal stroke, or nonfatal myocardial infarction.

Secondary Outcome:
Disability measured by Rankin scale.
Bleeding complications.

Results:
In the group assigned to receive 30 mg of aspirin, the frequency of death from vascular causes, nonfatal stroke, or nonfatal myocardial infarction was 228 of 1555 (14.7%) as compared with 240 of 1576 (15.2%) in the group assigned to receive 283 mg. There were slightly fewer major bleeding complications in the 30-mg group than in the 283-mg group (40 vs. 53), and significantly fewer reports of minor bleeding (49 vs. 84). Patients on atenolol had a risk of 97/732 (13.3%) for the combined outcome event versus a risk of 95/741 (12.8%) for those on placebo (adjusted hazard ratio, 1.00; 95% confidence interval, 0.76-1.33).

Source of Information:
Published report 1991.

Web Links and Publications:

We need stronger predictors of major vascular events in patients with a recent transient ischemic attack or nondisabling stroke. Dutch TIA Trial Study Group.
Stroke 1997 Apr;28(4):774-6

Silent infarction on a second CT scan in 91 patients without manifest stroke in the Dutch TIA trial.
Clin Neurol Neurosurg. 1994 Aug;96(3):219-21.

Predictive value of clinical history and electrocardiogram in patients with transient ischemic attack or minor ischemic stroke for subsequent cardiac and cerebral ischemic events. The Dutch TIA Trial Study Group.
Arch Neurol. 1994 Apr;51(4):333-41.

Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. The Dutch TIA Trial Study Group.
Stroke 1993 Apr;24(4):543-8.

Predictors of major vascular events in patients with a transient ischemic attack or nondisabling stroke. The Dutch TIA Trial Study Group.
Stroke 1993 Apr;24(4):527-31.

Does cerebral infarction after a previous warning occur in the same vascular territory?
Stroke 1993 Mar;24(3):351-4.

Silent stroke in patients with transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group.
Stroke 1992 Sep;23(9):1220-4.

Hypodensity of the cerebral white matter in patients with transient ischemic attack or minor stroke: influence on the rate of subsequent stroke. Dutch TIA Trial Study Group.
Ann Neurol. 1992 Aug;32(2):177-83.

TIA, RIND, minor stroke: a continuum, or different subgroups? Dutch TIA Study Group.
J Neurol Neurosurg Psychiatry. 1992 Feb;55(2):95-7.

A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group.
N Engl J Med. 1991 Oct 31;325(18):1261-6.

Transient ischemic attacks with and without a relevant infarct on computed tomographic scans cannot be distinguished clinically. Dutch Transient Ischemic Attack Study Group.
Arch Neurol. 1991 Sep;48(9):916-20.

The Dutch TIA trial: protective effects of low-dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. The Dutch TIA Study Group.
Stroke 1988 Apr;19(4):512-7.

This information last updated on: 5/14/2001

UID: 277